OA11598A - HIV vaccine. - Google Patents

HIV vaccine. Download PDF

Info

Publication number: OA11598A
Authority: OA; OAPI
Prior art keywords: nss; hiv; cytolytic; virus; retrovirus
Prior art date: 1998-08-12

Application number

OA1200100041A

Other languages

English (en)

Inventor

Chil-Yong Kang

Yan Li

Original Assignee

Univ Western Ontario

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-12

Filing date

1999-08-12

Publication date

2004-07-30

1999-08-12 Application filed by Univ Western Ontario filed Critical Univ Western Ontario

2004-07-30 Publication of OA11598A publication Critical patent/OA11598A/en

Links

229940033330 HIV vaccine Drugs 0.000 title abstract description 3
108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 81
230000001461 cytolytic effect Effects 0.000 claims abstract description 62
241000700605 Viruses Species 0.000 claims abstract description 61
229960005486 vaccine Drugs 0.000 claims abstract description 40
101710121417 Envelope glycoprotein Proteins 0.000 claims abstract description 26
108700004028 nef Genes Proteins 0.000 claims abstract description 17
101150023385 nef gene Proteins 0.000 claims abstract description 16
102100021696 Syncytin-1 Human genes 0.000 claims abstract 3
210000004027 cell Anatomy 0.000 claims description 73
241001430294 unidentified retrovirus Species 0.000 claims description 53
108090000623 proteins and genes Proteins 0.000 claims description 40
238000000034 method Methods 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 24
108091034117 Oligonucleotide Proteins 0.000 claims description 18
150000001413 amino acids Chemical class 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 16
108010002386 Interleukin-3 Proteins 0.000 claims description 11
239000005557 antagonist Substances 0.000 claims description 11
VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical group NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 claims description 11
108090000288 Glycoproteins Proteins 0.000 claims description 10
102000003886 Glycoproteins Human genes 0.000 claims description 10
239000000074 antisense oligonucleotide Substances 0.000 claims description 10
238000012230 antisense oligonucleotides Methods 0.000 claims description 10
238000012986 modification Methods 0.000 claims description 10
230000004048 modification Effects 0.000 claims description 10
206010038997 Retroviral infections Diseases 0.000 claims description 8
150000007523 nucleic acids Chemical group 0.000 claims description 8
108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 2
230000000295 complement effect Effects 0.000 claims description 2
230000002147 killing effect Effects 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 6
108700010908 HIV-1 proteins Proteins 0.000 claims 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
210000004102 animal cell Anatomy 0.000 claims 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 50
102100034349 Integrase Human genes 0.000 description 24
108020004414 DNA Proteins 0.000 description 18
239000012634 fragment Substances 0.000 description 17
239000013612 plasmid Substances 0.000 description 17
241000725303 Human immunodeficiency virus Species 0.000 description 14
238000010276 construction Methods 0.000 description 11
108010036176 Melitten Proteins 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
230000006907 apoptotic process Effects 0.000 description 9
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
241000711975 Vesicular stomatitis virus Species 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000000047 product Substances 0.000 description 7
241000701447 unidentified baculovirus Species 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
231100000135 cytotoxicity Toxicity 0.000 description 5
230000003013 cytotoxicity Effects 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108091093037 Peptide nucleic acid Proteins 0.000 description 4
102100027722 Small glutamine-rich tetratricopeptide repeat-containing protein alpha Human genes 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
108700004025 env Genes Proteins 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229930024421 Adenine Natural products 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
238000000246 agarose gel electrophoresis Methods 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
230000030833 cell death Effects 0.000 description 3
101150030339 env gene Proteins 0.000 description 3
125000001475 halogen functional group Chemical group 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
230000001566 pro-viral effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
-1 8-substitutedadenines Chemical class 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
208000000474 Poliomyelitis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
238000002823 phage display Methods 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
229960001539 poliomyelitis vaccine Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
108700026222 vpu Genes Proteins 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
WYDKPTZGVLTYPG-UHFFFAOYSA-N 2,8-diamino-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(N)N2 WYDKPTZGVLTYPG-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
XZWMZFQOHTWGQE-UHFFFAOYSA-N 6-azathymine Chemical compound CC1=NNC(=O)NC1=O XZWMZFQOHTWGQE-UHFFFAOYSA-N 0.000 description 1
SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
PFUVOLUPRFCPMN-UHFFFAOYSA-N 7h-purine-6,8-diamine Chemical compound C1=NC(N)=C2NC(N)=NC2=N1 PFUVOLUPRFCPMN-UHFFFAOYSA-N 0.000 description 1
RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
101150082239 G gene Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
229940033332 HIV-1 vaccine Drugs 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282553 Macaca Species 0.000 description 1
101150094382 NSS gene Proteins 0.000 description 1
101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
101710192141 Protein Nef Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940029583 inactivated polio vaccine Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
102000021127 protein binding proteins Human genes 0.000 description 1
108091011138 protein binding proteins Proteins 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
101150090490 vpu gene Proteins 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

OA1200100041A 1998-08-12 1999-08-12 HIV vaccine. OA11598A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9623598P	1998-08-12	1998-08-12

Publications (1)

Publication Number	Publication Date
OA11598A true OA11598A (en)	2004-07-30

Family

ID=22256483

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100041A OA11598A (en)	1998-08-12	1999-08-12	HIV vaccine.

Country Status (14)

Country	Link
EP (1)	EP1105498B1 (fr)
KR (1)	KR100689249B1 (fr)
CN (1)	CN1206355C (fr)
AP (1)	AP1561A (fr)
AT (1)	ATE431415T1 (fr)
AU (1)	AU5274099A (fr)
CA (1)	CA2339850C (fr)
DE (1)	DE69940886D1 (fr)
DK (1)	DK1105498T3 (fr)
ES (1)	ES2327300T3 (fr)
OA (1)	OA11598A (fr)
PT (1)	PT1105498E (fr)
WO (1)	WO2000009703A1 (fr)
ZA (1)	ZA200100941B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7608273B2 (en) *	1998-08-12	2009-10-27	University Of Western Ontario	Recombinant lentivirus encoding modified GP 120 signal sequences
WO2005012535A2 (fr) *	2003-08-01	2005-02-10	Phytovation B.V.	Procede d'elaboration de virus vivants attenues, et utilisation de particules virales ainsi obtenues
CN111701016A (zh) *	2020-06-28	2020-09-25	张全志	逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994017825A1 (fr) *	1993-02-05	1994-08-18	The Regents Of The University Of California	Mutants de genes multiples du virus d'immunodeficience humaine utilises dans un vaccin

1999
- 1999-08-12 AT AT99938094T patent/ATE431415T1/de active
- 1999-08-12 PT PT99938094T patent/PT1105498E/pt unknown
- 1999-08-12 OA OA1200100041A patent/OA11598A/en unknown
- 1999-08-12 DK DK99938094T patent/DK1105498T3/da active
- 1999-08-12 EP EP99938094A patent/EP1105498B1/fr not_active Expired - Lifetime
- 1999-08-12 KR KR1020017001836A patent/KR100689249B1/ko not_active Expired - Fee Related
- 1999-08-12 DE DE69940886T patent/DE69940886D1/de not_active Expired - Lifetime
- 1999-08-12 AP APAP/P/2001/002076A patent/AP1561A/en active
- 1999-08-12 CN CNB998108529A patent/CN1206355C/zh not_active Expired - Lifetime
- 1999-08-12 ES ES99938094T patent/ES2327300T3/es not_active Expired - Lifetime
- 1999-08-12 AU AU52740/99A patent/AU5274099A/en not_active Abandoned
- 1999-08-12 WO PCT/CA1999/000746 patent/WO2000009703A1/fr not_active Ceased
- 1999-08-12 CA CA2339850A patent/CA2339850C/fr not_active Expired - Lifetime
2001
- 2001-02-02 ZA ZA200100941A patent/ZA200100941B/en unknown

Also Published As

Publication number	Publication date
KR100689249B1 (ko)	2007-03-08
AP2001002076A0 (en)	2001-03-31
ES2327300T3 (es)	2009-10-27
CN1318104A (zh)	2001-10-17
PT1105498E (pt)	2009-08-13
ZA200100941B (en)	2002-02-04
EP1105498A1 (fr)	2001-06-13
ATE431415T1 (de)	2009-05-15
AU5274099A (en)	2000-03-06
CA2339850A1 (fr)	2000-02-24
KR20010072436A (ko)	2001-07-31
DE69940886D1 (en)	2009-06-25
CN1206355C (zh)	2005-06-15
WO2000009703A1 (fr)	2000-02-24
EP1105498B1 (fr)	2009-05-13
CA2339850C (fr)	2011-10-04
DK1105498T3 (da)	2009-08-31
AP1561A (en)	2006-02-01

Publication	Publication Date	Title
US10160788B2 (en)	2018-12-25	Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
Shafferman et al.	1991	Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.
AU2018283811B2 (en)	2022-10-20	Poxvirus vectors encoding HIV antigens, and methods of use thereof
US20030158134A1 (en)	2003-08-21	Vaccine for the prophylactic or therapeutic immunization against hiv
Johnson et al.	1992	Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
US20040191269A1 (en)	2004-09-30	Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
NZ525751A (en)	2004-10-29	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
KR20100109555A (ko)	2010-10-08	백신
US7067134B1 (en)	2006-06-27	HIV vaccine
US20040223977A1 (en)	2004-11-11	Fusion peptide HIV vaccines
Boeri et al.	1992	In vivo genetic variability of the human immunodeficiency virus type 2 V3 region
CA2304125A1 (fr)	1999-03-25	Materiau genetique sous forme de cassettes d'immunisation a base d'adn de vif attenue pour des vaccins genetiques
US5876724A (en)	1999-03-02	Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
EP0613378A1 (fr)	1994-09-07	Induction de protection contre les infections virales par utilisation d'une synergie entre les proteines virales et les peptides viraux
CA2538840C (fr)	2014-02-18	Compositions issues d'un vaccin adn et leurs procedes d'utilisation
EP0472706B1 (fr)	1997-06-11	Induction de protection contre les infections virales
CA2339850C (fr)	2011-10-04	Vaccin anti-vih-1 recombinant et non cytolytique
ES2396915T3 (es)	2013-03-01	Secuencias consenso, antígenos y transgenes del VIH-1 del clado A
KR101370817B1 (ko)	2014-03-07	Ｈｉｖ 백신
EP2788372B1 (fr)	2019-07-10	Protéines env lentivirales mutées et applications comme médicaments
US20070099276A1 (en)	2007-05-03	Retrovirus-like particles and retroviral vaccines
WO2005051419A1 (fr)	2005-06-09	Particules de type retrovirus et vaccins retroviraux
WO1994012513A1 (fr)	1994-06-09	Therapiedu sida basee sur l'administration de peptides ma du vih
WO1992000098A1 (fr)	1992-01-09	Methodes destinees a provoquer une reponse immunitaire au virus du sida
JPWO1998022596A1 (ja)	2000-03-28	組み換えワクシニアウイルス、これを用いたＧａｇタンパク質粒子構造物の製造方法、当該製造方法により得られた粒子、およびその利用